CA2926571C - Non-platinum-based anti-cancer compounds for use in targeted chemotherapy - Google Patents
Non-platinum-based anti-cancer compounds for use in targeted chemotherapy Download PDFInfo
- Publication number
- CA2926571C CA2926571C CA2926571A CA2926571A CA2926571C CA 2926571 C CA2926571 C CA 2926571C CA 2926571 A CA2926571 A CA 2926571A CA 2926571 A CA2926571 A CA 2926571A CA 2926571 C CA2926571 C CA 2926571C
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- npb
- cells
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887988P | 2013-10-08 | 2013-10-08 | |
| US61/887,988 | 2013-10-08 | ||
| PCT/CA2014/050974 WO2015051458A1 (en) | 2013-10-08 | 2014-10-08 | Non-platimun-based anti-cancer compounds for use in targeted chemotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2926571A1 CA2926571A1 (en) | 2015-04-16 |
| CA2926571C true CA2926571C (en) | 2022-05-17 |
Family
ID=52812401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2926571A Active CA2926571C (en) | 2013-10-08 | 2014-10-08 | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10463662B2 (https=) |
| EP (2) | EP3578176A1 (https=) |
| JP (1) | JP6765302B2 (https=) |
| KR (1) | KR102307387B1 (https=) |
| CN (2) | CN114380700A (https=) |
| AU (1) | AU2014334461B2 (https=) |
| CA (1) | CA2926571C (https=) |
| WO (1) | WO2015051458A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017007756A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc | Hetero-halo inhibitors of histone deacetylase |
| MX388576B (es) | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| US11168068B2 (en) | 2016-07-18 | 2021-11-09 | Janssen Pharmaceutica Nv | Tau PET imaging ligands |
| HUE057849T2 (hu) | 2017-01-11 | 2022-06-28 | Alkermes Inc | Hiszton deacetiláz biciklusos gátlói |
| EA202190196A1 (ru) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| LT3664802T (lt) | 2017-08-07 | 2022-06-27 | Alkermes, Inc. | Bicikliniai histonų deacetilazės inhibitoriai |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3822261A (en) * | 1972-10-30 | 1974-07-02 | Dow Chemical Co | 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines |
| EP0743855A1 (en) * | 1994-01-03 | 1996-11-27 | Acea Pharmaceuticals, Inc. | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor |
| US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
| DE102004054545A1 (de) * | 2004-09-16 | 2006-04-06 | Max-Delbrück-Centrum für Molekulare Medizin | Änderung des Beladungszustandes von MHC-Molekülen |
| US20060089316A1 (en) * | 2004-10-25 | 2006-04-27 | Brown Truman R | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| EP1853583B1 (en) * | 2005-02-16 | 2011-09-07 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| CN101611007A (zh) | 2006-12-20 | 2009-12-23 | 先灵公司 | 新颖的jnk抑制剂 |
| MX2009013332A (es) * | 2007-06-08 | 2010-01-25 | Mannkind Corp | Inhibidores de ire-1 alfa. |
| ATE551336T1 (de) * | 2007-08-16 | 2012-04-15 | Hoffmann La Roche | Substituierte hydantoine |
| DK200801600A (en) | 2008-11-17 | 2010-05-18 | Engkilde Kaare | Method for treatment of inflammatory diseases |
| EP2493862B1 (en) * | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| WO2012096813A1 (en) * | 2011-01-11 | 2012-07-19 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
| CN105164107B (zh) | 2012-12-20 | 2017-12-05 | 卢庆彬 | 用于与放射结合使用的放射增敏剂化合物 |
-
2014
- 2014-10-08 CN CN202111465211.9A patent/CN114380700A/zh active Pending
- 2014-10-08 CN CN201480066862.2A patent/CN106232581A/zh active Pending
- 2014-10-08 AU AU2014334461A patent/AU2014334461B2/en not_active Ceased
- 2014-10-08 CA CA2926571A patent/CA2926571C/en active Active
- 2014-10-08 US US15/028,169 patent/US10463662B2/en active Active
- 2014-10-08 WO PCT/CA2014/050974 patent/WO2015051458A1/en not_active Ceased
- 2014-10-08 EP EP19188591.2A patent/EP3578176A1/en not_active Withdrawn
- 2014-10-08 JP JP2016522040A patent/JP6765302B2/ja not_active Expired - Fee Related
- 2014-10-08 KR KR1020167012036A patent/KR102307387B1/ko not_active Expired - Fee Related
- 2014-10-08 EP EP14852850.8A patent/EP3055287B1/en active Active
-
2019
- 2019-09-18 US US16/574,800 patent/US11446294B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200009133A1 (en) | 2020-01-09 |
| EP3055287B1 (en) | 2019-11-06 |
| KR102307387B1 (ko) | 2021-09-30 |
| AU2014334461A1 (en) | 2016-04-28 |
| EP3055287A1 (en) | 2016-08-17 |
| KR20160070784A (ko) | 2016-06-20 |
| CN106232581A (zh) | 2016-12-14 |
| JP6765302B2 (ja) | 2020-10-07 |
| EP3055287A4 (en) | 2017-04-12 |
| CN114380700A (zh) | 2022-04-22 |
| JP2016534048A (ja) | 2016-11-04 |
| EP3578176A1 (en) | 2019-12-11 |
| US10463662B2 (en) | 2019-11-05 |
| WO2015051458A1 (en) | 2015-04-16 |
| US20160235743A1 (en) | 2016-08-18 |
| CA2926571A1 (en) | 2015-04-16 |
| US11446294B2 (en) | 2022-09-20 |
| AU2014334461B2 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2926571C (en) | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | |
| US9655965B2 (en) | Radiosensitizer compounds for use in combination with radiation | |
| Rodríguez‐Enríquez et al. | Targeting of cancer energy metabolism | |
| KR20220008869A (ko) | 항암 핵 호르몬 수용체-표적화 화합물 | |
| WO2012064898A1 (en) | Singleton inhibitors of sumoylation enzymes and methods for their use | |
| WO2008033440A2 (en) | Treatment of hyperproliferative diseases with anthraquinones | |
| EP2890374B1 (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell | |
| US20120156311A1 (en) | Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor | |
| CN104602710A (zh) | 癌症治疗 | |
| JP2019514969A (ja) | 分子イメージング及びがんの免疫療法のためのδオピオイド受容体標的化薬 | |
| Lv et al. | Hypoxia-responsive paclitaxel prodrugs: linker evaluation and NIR-triggered self-amplifying photodynamic-chemotherapy nanoplatform | |
| TW202108570A (zh) | 抗癌核荷爾蒙受體標靶化合物 | |
| WO2026089661A1 (en) | Cascade x-ray energy transfer-based radio-afterglow nanoparticles for cancer theranostics | |
| Qian et al. | Precision mitochondrial reprogramming via a ROS-amplifying Pt (iv) nanoplatform potentiates tri-modal therapy to overcome Pt resistance in HCC | |
| US20070225268A1 (en) | Method to treat neoplasms via gadolinium stereotactic synchrotron radiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191008 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251119 |